Cipla receives regulatory approval for launch of Ciplenza in India to treat mild to moderate COVID-19 Kumar Jeetendra | July 24, 2020 Mumbai, India; July 24, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ, hereinafter referred to as “Cipla”), today announced that it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza. The accelerated approval for manufacturing and marketing of …
